Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 5639875, 13 pages
http://dx.doi.org/10.1155/2016/5639875
Review Article

Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus

1Sorbonne Universités, UPMC Univ Paris 06, Laboratoire des Biomolécules, 4 Place Jussieu, 75005 Paris, France
2Département de Chimie, Ecole Normale Supérieure, PSL Research University, 24 Rue Lhomond, 75005 Paris, France
3CNRS, UMR 7203 Laboratoire des Biomolécules, 75005 Paris, France

Received 27 November 2014; Accepted 3 March 2015

Academic Editor: Hiroshi Okamoto

Copyright © 2016 Lucie Caillon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Chiti and C. M. Dobson, “Protein misfolding, functional amyloid, and human disease,” Annual Review of Biochemistry, vol. 75, pp. 333–366, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. D. Sipe, “Amyloidosis,” Critical Reviews in Clinical Laboratory Sciences, vol. 31, no. 4, pp. 325–354, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Selkoe, “Folding proteins in fatal ways,” Nature, vol. 426, no. 6968, pp. 900–904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. W. M. Höppener, B. Ahrén, and C. J. M. Lips, “Islet amyloid and type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 343, no. 6, pp. 411–419, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. G. G. Glenner, E. D. Eanes, H. A. Bladen, R. P. Linke, and J. D. Termine, “β-pleated sheet fibrils. A comparison of native amyloid with synthetic protein fibrils,” Journal of Histochemistry & Cytochemistry, vol. 22, no. 12, pp. 1141–1158, 1974. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Luca, W.-M. Yau, R. Leapman, and R. Tycko, “Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR,” Biochemistry, vol. 46, no. 47, pp. 13505–13522, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. G. J. S. Cooper, A. C. Willis, A. Clark, R. C. Turner, R. B. Sim, and K. B. M. Reid, “Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 23, pp. 8628–8632, 1987. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Westermark, C. Wernstedt, E. Wilander, D. W. Hayden, T. D. O'Brien, and K. H. Johnson, “Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 11, pp. 3881–3885, 1987. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Westermark, C. Wernstedt, E. Wilander, and K. Sletten, “A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas,” Biochemical and Biophysical Research Communications, vol. 140, no. 3, pp. 827–831, 1986. View at Publisher · View at Google Scholar · View at Scopus
  10. G. J. S. Cooper, B. Leighton, G. D. Dimitriadis et al., “Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 20, pp. 7763–7766, 1988. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Westermark, A. Andersson, and G. T. Westermark, “Islet amyloid polypeptide, islet amyloid, and diabetes mellitus,” Physiological Reviews, vol. 91, no. 3, pp. 795–826, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Samsom, L. A. Szarka, M. Camilleri, A. Vella, A. R. Zinsmeister, and R. A. Rizza, “Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 278, no. 6, pp. G946–G951, 2000. View at Google Scholar · View at Scopus
  13. I. Chapman, B. Parker, S. Doran et al., “Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes,” Diabetologia, vol. 48, no. 5, pp. 838–848, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Chapman, B. Parker, S. Doran et al., “Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects,” Obesity, vol. 15, no. 5, pp. 1179–1186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Åkesson, G. Panagiotidis, P. Westermark, and I. Lundquist, “Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets,” Regulatory Peptides, vol. 111, no. 1–3, pp. 55–60, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. P. A. Rushing, M. M. Hagan, R. J. Seeley et al., “Inhibition of central amylin signaling increases food intake and body adiposity in rats,” Endocrinology, vol. 142, no. 11, pp. 5035–5038, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. R. A. Ritzel, J. J. Meier, C.-Y. Lin, J. D. Veldhuis, and P. C. Butler, “Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets,” Diabetes, vol. 56, no. 1, pp. 65–71, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. P. J. Wookey, C. Tikellis, D. U. He-Cheng, H.-F. Qin, P. M. Sexton, and M. E. Cooper, “Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin,” The American Journal of Physiology, vol. 270, no. 2, pp. F289–F294, 1996. View at Google Scholar · View at Scopus
  19. P. M. Sexton, G. Paxinos, X.-F. Huang, and F. A. O. Mendelsohn, “In vitro autoradiographic localization of calcitonin binding sites in human medulla oblongata,” Journal of Comparative Neurology, vol. 341, no. 4, pp. 449–463, 1994. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Paxinos, S. Y. Chai, G. Christopoulos et al., “In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain,” Journal of Chemical Neuroanatomy, vol. 27, no. 4, pp. 217–236, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Stridsberg, S. Sandler, and E. Wilander, “Cosecretion of islet amyloid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of β-cell function,” Regulatory Peptides, vol. 45, no. 3, pp. 363–370, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Lukinius, E. Wilander, G. T. Westermark, U. Engstrom, and P. Westermark, “Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets,” Diabetologia, vol. 32, no. 4, pp. 240–244, 1989. View at Publisher · View at Google Scholar · View at Scopus
  23. S. E. Kahn, D. A. D'Alessio, M. W. Schwartz et al., “Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells,” Diabetes, vol. 39, no. 5, pp. 634–638, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Furuta, H. Yano, A. Zhou et al., “Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 13, pp. 6646–6651, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Marcinkiewicz, D. Ramla, N. G. Seidah, and M. Chrétien, “Developmental expression of the prohormone convertases PC1 and PC2 in mouse pancreatic islets,” Endocrinology, vol. 135, no. 4, pp. 1651–1660, 1994. View at Google Scholar · View at Scopus
  26. L. Marzban, C. J. Rhodes, D. F. Steiner, L. Haataja, P. A. Halban, and C. B. Verchere, “Impaired NH2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death,” Diabetes, vol. 55, no. 8, pp. 2192–2201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. J. F. Paulsson, A. Andersson, P. Westermark, and G. T. Westermark, “Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets,” Diabetologia, vol. 49, no. 6, pp. 1237–1246, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. E. Higham, E. T. A. S. Jaikaran, P. E. Fraser, M. Gross, and A. Clark, “Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils,” FEBS Letters, vol. 470, no. 1, pp. 55–60, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Goldsbury, K. Goldie, J. Pellaud et al., “Amyloid fibril formation from full-length and fragments of amylin,” Journal of Structural Biology, vol. 130, no. 2-3, pp. 352–362, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Kayed, J. Bernhagen, N. Greenfield et al., “Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro,” Journal of Molecular Biology, vol. 287, no. 4, pp. 781–796, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Kayed, A. Pensalfini, L. Margol et al., “Annular protofibrils area structurally and functionally distinct type of amyloid oligomer,” The Journal of Biological Chemistry, vol. 284, no. 7, pp. 4230–4237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. D. Knight, J. A. Hebda, and A. D. Miranker, “Conserved and cooperative assembly of membrane-bound α-helical states of islet amyloid polypeptide,” Biochemistry, vol. 45, no. 31, pp. 9496–9508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Porat, A. Stepensky, F.-X. Ding, F. Naider, and E. Gazit, “Completely different amyloidogenic potential of nearly identical peptide fragments,” Biopolymers, vol. 69, no. 2, pp. 161–164, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. J. D. Green, L. Kreplak, C. Goldsbury et al., “Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide,” Journal of Molecular Biology, vol. 342, no. 3, pp. 877–887, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. D. Green, C. Goldsbury, J. Kistler, G. J. S. Cooper, and U. Aebi, “Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation,” The Journal of Biological Chemistry, vol. 279, no. 13, pp. 12206–12212, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Anguiano, R. J. Nowak, and P. T. Lansbury Jr., “Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes,” Biochemistry, vol. 41, no. 38, pp. 11338–11343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Janson, R. H. Ashley, D. Harrison, S. McIntyre, and P. C. Butler, “The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles,” Diabetes, vol. 48, no. 3, pp. 491–498, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. C. S. Goldsbury, G. J. S. Cooper, K. N. Goldie et al., “Polymorphic fibrillar assembly of human amylin,” Journal of Structural Biology, vol. 119, no. 1, pp. 17–27, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. J. J. W. Wiltzius, S. A. Sievers, M. R. Sawaya et al., “Atomic structure of the cross-β spine of islet amyloid polypeptide (amylin),” Protein Science, vol. 17, no. 9, pp. 1467–1474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. A. Jayasinghe and R. Langen, “Lipid membranes modulate the structure of islet amyloid polypeptide,” Biochemistry, vol. 44, no. 36, pp. 12113–12119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Caillon, O. Lequin, and L. Khemtémourian, “Evaluation of membrane models and their composition for islet amyloid polypeptide-membrane aggregation,” Biochimica et Biophysica Acta—Biomembranes, vol. 1828, no. 9, pp. 2091–2098, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. S. M. Patil, S. Xu, S. R. Sheftic, and A. T. Alexandrescu, “Dynamic alpha-helix structure of micelle-bound human amylin,” The Journal of Biological Chemistry, vol. 284, no. 18, pp. 11982–11991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. R. P. R. Nanga, J. R. Brender, S. Vivekanandan, and A. Ramamoorthy, “Structure and membrane orientation of IAPP in its natively amidated form at physiological pH in a membrane environment,” Biochimica et Biophysica Acta, vol. 1808, no. 10, pp. 2337–2342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Quist, I. Doudevski, H. Lin et al., “Amyloid ion channels: a common structural link for protein-misfolding disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 30, pp. 10427–10432, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. S. B. Padrick and A. D. Miranker, “Islet amyloid: phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis,” Biochemistry, vol. 41, no. 14, pp. 4694–4703, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Naiki, K. Higuchi, M. Hosokawa, and T. Takeda, “Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T,” Analytical Biochemistry, vol. 177, no. 2, pp. 244–249, 1989. View at Publisher · View at Google Scholar · View at Scopus
  47. P. J. Marek, V. Patsalo, D. F. Green, and D. P. Raleigh, “Ionic strength effects on amyloid formation by amylin are a complicated interplay among debye screening, ion selectivity, and hofmeister effects,” Biochemistry, vol. 51, no. 43, pp. 8478–8490, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Khemtémourian, E. Doménech, J. P. F. Doux, M. C. Koorengevel, and J. A. Killian, “Low pH Acts as inhibitor of membrane damage induced by human islet amyloid polypeptide,” Journal of the American Chemical Society, vol. 133, no. 39, pp. 15598–15604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Sanke, G. I. Bell, C. Sample, A. H. Rubenstein, and D. F. Steiner, “An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing,” Journal of Biological Chemistry, vol. 263, no. 33, pp. 17243–17246, 1988. View at Google Scholar · View at Scopus
  50. P. Westermark, U. Engstrom, K. H. Johnson, G. T. Westermark, and C. Betsholtz, “Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 13, pp. 5036–5040, 1990. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Betsholtz, L. Christmansson, U. Engstrom et al., “Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species,” FEBS Letters, vol. 251, no. 1-2, pp. 261–264, 1989. View at Publisher · View at Google Scholar · View at Scopus
  52. M. F. M. Engel, H. Yigittop, R. C. Elgersma et al., “Islet amyloid polypeptide inserts into phospholipid monolayers as monomer,” Journal of Molecular Biology, vol. 356, no. 3, pp. 783–789, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Khemtémourian, M. F. M. Engel, R. M. J. Liskamp, J. W. M. Höppener, and J. A. Killian, “The N-terminal fragment of human islet amyloid polypeptide is non-fibrillogenic in the presence of membranes and does not cause leakage of bilayers of physiologically relevant lipid composition,” Biochimica et Biophysica Acta: Biomembranes, vol. 1798, no. 9, pp. 1805–1811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. M. R. Nilsson and D. P. Raleigh, “Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin,” Journal of Molecular Biology, vol. 294, no. 5, pp. 1375–1385, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. R. P. R. Nanga, J. R. Brender, J. Xu, G. Veglia, and A. Ramamoorthy, “Structures of rat and human islet amyloid polypeptide IAPP1-19 in micelles by NMR spectroscopy,” Biochemistry, vol. 47, no. 48, pp. 12689–12697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. E. T. A. S. Jaikaran, C. E. Higham, L. C. Serpell et al., “Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis,” Journal of Molecular Biology, vol. 308, no. 3, pp. 515–525, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Abedini and D. P. Raleigh, “The role of His-18 in amyloid formation by human islet amyloid polypeptide,” Biochemistry, vol. 44, no. 49, pp. 16284–16291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. S. M. Tracz, A. Abedini, M. Driscoll, and D. P. Raleigh, “Role of aromatic interactions in amyloid formation by peptides derived from human amylin,” Biochemistry, vol. 43, no. 50, pp. 15901–15908, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Marek, A. Abedini, B. Song et al., “Aromatic interactions are not required for amyloid fibril formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology,” Biochemistry, vol. 46, no. 11, pp. 3255–3261, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. L.-H. Tu and D. P. Raleigh, “Role of aromatic interactions in amyloid formation by islet amyloid polypeptide,” Biochemistry, vol. 52, no. 2, pp. 333–342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Sakagashira, H. J. Hiddinga, K. Tateishi et al., “S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin,” The American Journal of Pathology, vol. 157, no. 6, pp. 2101–2109, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. B. W. Koo and A. D. Miranker, “Contribution of the intrinsic disulfide to the assembly mechanism of islet amyloid,” Protein Science, vol. 14, no. 1, pp. 231–239, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Abedini and D. P. Raleigh, “Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP?” Journal of Molecular Biology, vol. 355, no. 2, pp. 274–281, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Green, C. Goldsbury, T. Mini et al., “Full-length rat amylin forms fibrils following substitution of single residues from human amylin,” Journal of Molecular Biology, vol. 326, no. 4, pp. 1147–1156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. J. F. Paulsson and G. T. Westermark, “Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation,” Diabetes, vol. 54, no. 7, pp. 2117–2125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. I. T. Yonemoto, G. J. A. Kroon, H. J. Dyson, W. E. Balch, and J. W. Kelly, “Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state,” Biochemistry, vol. 47, no. 37, pp. 9900–9910, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Krampert, J. Bernhagen, J. Schmucker et al., “Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP),” Chemistry & Biology, vol. 7, no. 11, pp. 855–871, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Meng, A. Abedini, B. Song, and D. P. Raleigh, “Amyloid formation by pro-islet amyloid polypeptide processing intermediates: Examination of the role of protein heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes,” Biochemistry, vol. 46, no. 43, pp. 12091–12099, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Khemtémourian, G. L. Casarramona, D. P. L. Suylen et al., “Impaired processing of human pro-islet amyloid polypeptide is not a causative factor for fibril formation or membrane damage in vitro,” Biochemistry, vol. 48, no. 46, pp. 10918–10925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. A. N. Roberts, B. Leighton, J. A. Todd et al., “Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 24, pp. 9662–9666, 1989. View at Publisher · View at Google Scholar · View at Scopus
  71. J. D. Knight and A. D. Miranker, “Phospholipid catalysis of diabetic amyloid assembly,” Journal of Molecular Biology, vol. 341, no. 5, pp. 1175–1187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. E. Sparr, M. F. M. Engel, D. V. Sakharov et al., “Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers,” FEBS Letters, vol. 577, no. 1-2, pp. 117–120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Sasahara, K. Morigaki, T. Okazaki, and D. Hamada, “Binding of islet amyloid polypeptide to supported lipid bilayers and amyloid aggregation at the membranes,” Biochemistry, vol. 51, no. 35, pp. 6908–6919, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Ahmad, A. Ahmad, S. Singh, M. Arshad, A. H. Khan, and R. H. Khan, “A mechanistic approach for islet amyloid polypeptide aggregation to develop anti-amyloidogenic agents for type-2 diabetes,” Biochimie, vol. 93, no. 5, pp. 793–805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Khemtémourian, M. F. M. Engel, J. A. W. Kruijtzer, J. W. M. Höppener, R. M. J. Liskamp, and J. A. Killian, “The role of the disulfide bond in the interaction of islet amyloid polypeptide with membranes,” European Biophysics Journal, vol. 39, no. 9, pp. 1359–1364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Zhao, E. K. J. Tuominen, and P. K. J. Kinnunen, “Formation of amyloid fibers triggered by phosphatidylserine-containing membranes,” Biochemistry, vol. 43, no. 32, pp. 10302–10307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. M. F. M. Sciacca, J. R. Brender, D.-K. Lee, and A. Ramamoorthy, “Phosphatidylethanolamine enhances amyloid fiber-dependent membrane fragmentation,” Biochemistry, vol. 51, no. 39, pp. 7676–7684, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. N. Arispe, E. Rojas, and H. B. Pollard, “Alzheimer disease amyloid β protein forms calcium channels in bilayer-membranes: blockade by tromethamine and aluminum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 2, pp. 567–571, 1993. View at Publisher · View at Google Scholar · View at Scopus
  79. T. A. Mirzabekov, M.-C. Lin, and B. L. Kagan, “Pore formation by the cytotoxic islet amyloid peptide amylin,” The Journal of Biological Chemistry, vol. 271, no. 4, pp. 1988–1992, 1996. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Kawahara, Y. Kuroda, N. Arispe, and E. Rojas, “Alzheimer's β-amyloid, human islet amylin, and priori protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line,” The Journal of Biological Chemistry, vol. 275, no. 19, pp. 14077–14083, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Arispe, H. B. Pollard, and E. Rojas, “Giant multilevel cation channels formed by Alzheimer-disease amyloid beta-protein [a-beta-P-(1-40)] in bilayer-membranes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 22, pp. 10573–10577, 1993. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Kayed, Y. Sokolov, B. Edmonds et al., “Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases,” The Journal of Biological Chemistry, vol. 279, no. 45, pp. 46363–46366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Kayed, E. Head, J. L. Thompson et al., “Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis,” Science, vol. 300, no. 5618, pp. 486–489, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. M. F. M. Engel, L. Khemtémourian, C. C. Kleijer et al., “Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 16, pp. 6033–6038, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Jan, O. Adolfsson, I. Allaman et al., “Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species,” The Journal of Biological Chemistry, vol. 286, no. 10, pp. 8585–8596, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. L. Khemtémourian, J. A. Killian, J. W. Höppener, and M. F. M. Engel, “Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in β-cell death in type 2 diabetes mellitus,” Experimental Diabetes Research, vol. 2008, Article ID 421287, 9 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. G. P. Gellermann, T. R. Appel, A. Tannert et al., “Raft lipids as common components of human extracellular amyloid fibrils,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 18, pp. 6297–6302, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. R. Friedman, R. Pellarin, and A. Caflisch, “Amyloid aggregation on lipid bilayers and its impact on membrane permeability,” Journal of Molecular Biology, vol. 387, no. 2, pp. 407–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. E. Law, S. Lu, T. J. Kieffer et al., “Differences between amyloid toxicity in alpha and beta cells in human and mouse islets and the role of caspase-3,” Diabetologia, vol. 53, no. 7, pp. 1415–1427, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. J. F. Rivera, T. Gurlo, M. Daval et al., “Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic Β-cells: Protective role of p62-positive cytoplasmic inclusions,” Cell Death and Differentiation, vol. 18, no. 3, pp. 415–426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Zhang, J. Liu, M. Dragunow, and G. J. S. Cooper, “Fibrillogenic amylin evokes islet β-cell apoptosis through linked activation of a caspase cascade and JNK1,” The Journal of Biological Chemistry, vol. 278, no. 52, pp. 52810–52819, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. S. L. Subramanian, S. Zraika, K. Aston-Mourney, J. Udayasankar, and S. E. Kahn, “CJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets,” Diabetologia, vol. 55, no. 1, pp. 166–174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. Y. J. Park, S. Lee, T. J. Kieffer et al., “Deletion of Fas protects islet beta cells from cytotoxic effects of human islet amyloid polypeptide,” Diabetologia, vol. 55, no. 4, pp. 1035–1047, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. C. J. Huang, T. Gurlo, L. Haataja et al., “Calcium-activated calpain-2 is a mediator of beta cell dysfunction and apoptosis in type 2 diabetes,” The Journal of Biological Chemistry, vol. 285, no. 1, pp. 339–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Zraika, R. L. Hull, J. Udayasankar et al., “Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis,” Diabetologia, vol. 52, no. 4, pp. 626–635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Westwell-Roper, D. L. Dai, G. Soukhatcheva et al., “IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction,” Journal of Immunology, vol. 187, no. 5, pp. 2755–2765, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. S. L. Masters, A. Dunne, S. L. Subramanian et al., “Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β 2 in type 2 diabetes,” Nature Immunology, vol. 11, no. 10, pp. 897–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. M. M. Alhamadsheh, S. Connelly, A. Cho et al., “Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity,” Science Translational Medicine, vol. 3, no. 97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Bieschke, J. Russ, R. P. Friedrich et al., “EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 17, pp. 7710–7715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. A. K. Buell, E. K. Esbjörner, P. J. Riss et al., “Probing small molecule binding to amyloid fibrils,” Physical Chemistry Chemical Physics, vol. 13, no. 45, pp. 20044–20052, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Daval, S. Bedrood, T. Gurlo et al., “The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity,” Amyloid, vol. 17, no. 3-4, pp. 118–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. E. Gazit, “A possible role for π-stacking in the self-assembly of amyloid fibrils,” The FASEB Journal, vol. 16, no. 1, pp. 77–83, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Necula, R. Kayed, S. Milton, and C. G. Glabe, “Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct,” Journal of Biological Chemistry, vol. 282, no. 14, pp. 10311–10324, 2007. View at Google Scholar · View at Scopus
  104. D. Sellin, L.-M. Yan, A. Kapurniotu, and R. Winter, “Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin,” Biophysical Chemistry, vol. 150, no. 1–3, pp. 73–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Westermark, Z.-C. Li, G. T. Westermark, A. Leckström, and D. F. Steiner, “Effects of beta cell granule components on human islet amyloid polypeptide fibril formation,” FEBS Letters, vol. 379, no. 3, pp. 203–206, 1996. View at Publisher · View at Google Scholar · View at Scopus
  106. E. T. A. S. Jaikaran, M. R. Nilsson, and A. Clark, “Pancreatic β-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation,” Biochemical Journal, vol. 377, no. 3, pp. 709–716, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. C. Kudva, C. Mueske, P. C. Butler, and N. L. Eberhardt, “A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation,” Biochemical Journal, vol. 331, no. 3, pp. 809–813, 1998. View at Google Scholar · View at Scopus
  108. J. D. Knight, J. A. Williamson, and A. D. Miranker, “Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin,” Protein Science, vol. 17, no. 10, pp. 1850–1856, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. W. Cui, J.-W. Ma, P. Lei et al., “Insulin is a kinetic but not a thermodynamic inhibitor of amylin aggregation,” FEBS Journal, vol. 276, no. 12, pp. 3365–3371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Janciauskiene, S. Eriksson, E. Carlemalm, and B. Ahrén, “B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro,” Biochemical and Biophysical Research Communications, vol. 236, no. 3, pp. 580–585, 1997. View at Publisher · View at Google Scholar · View at Scopus
  111. A. C. Susa, C. Wu, S. L. Bernstein et al., “Defining the molecular basis of amyloid inhibitors: human islet amyloid polypeptide-insulin interactions,” Journal of the American Chemical Society, vol. 136, no. 37, pp. 12912–12919, 2014. View at Publisher · View at Google Scholar
  112. S. Gilead, H. Wolfenson, and E. Gazit, “Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin,” Angewandte Chemie—International Edition, vol. 45, no. 39, pp. 6476–6480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. A. H. Armstrong, J. Chen, A. F. McKoy, and M. H. Hecht, “Mutations that replace aromatic side chains promote aggregation of the Alzheimers Aβ peptide,” Biochemistry, vol. 50, no. 19, pp. 4058–4067, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. D. E. Ehrnhoefer, J. Bieschke, A. Boeddrich et al., “EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers,” Nature Structural & Molecular Biology, vol. 15, no. 6, pp. 558–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. S. A. Hudson, H. Ecroyd, F. C. Dehle, I. F. Musgrave, and J. A. Carver, “(-)-Epigallocatechin-3-gallate (EGCG) maintains κ-casein in its pre-fibrillar state without redirecting its aggregation pathway,” Journal of Molecular Biology, vol. 392, no. 3, pp. 689–700, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. J. M. Lopez del Amo, U. Fink, M. Dasari et al., “Structural properties of EGCG-induced, nontoxic Alzheimer's disease Aβ oligomers,” Journal of Molecular Biology, vol. 421, no. 4-5, pp. 517–524, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. M. F. M. Engel, C. C. Vandenakker, M. Schleeger, K. P. Velikov, G. H. Koenderink, and M. Bonn, “The polyphenol EGCG inhibits amyloid formation less efficiently at phospholipid interfaces than in bulk solution,” Journal of the American Chemical Society, vol. 134, no. 36, pp. 14781–14788, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. F. Meng, A. Abedini, A. Plesner, C. B. Verchere, and D. P. Raleigh, “The Flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity,” Biochemistry, vol. 49, no. 37, pp. 8127–8133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. H. Noor, P. Cao, and D. P. Raleigh, “Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid fibers,” Protein Science, vol. 21, no. 3, pp. 373–382, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. Y. Porat, Y. Mazor, S. Efrat, and E. Gazit, “Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions,” Biochemistry, vol. 43, no. 45, pp. 14454–14462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. P. Cao, F. Meng, A. Abedini, and D. P. Raleigh, “The ability of rodent islet amyloid polypeptide to inhibit amyloid formation by human islet amyloid polypeptide has important implications for the mechanism of amyloid formation and the design of inhibitors,” Biochemistry, vol. 49, no. 5, pp. 872–881, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Gilead and E. Gazit, “Inhibition of amyloid fibril formation by peptide analogues modified with alpha-aminoisobutyric acid,” Angewandte Chemie International Edition, vol. 43, no. 31, pp. 4041–4044, 2004. View at Publisher · View at Google Scholar · View at Scopus
  123. L.-M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, and A. Kapurniotu, “Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2046–2051, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. X. Li, L. Ma, W. Zheng, and T. Chen, “Inhibition of islet amyloid polypeptide fibril formation by selenium-containing phycocyanin and prevention of beta cell apoptosis,” Biomaterials, vol. 35, no. 30, pp. 8596–8604, 2014. View at Publisher · View at Google Scholar
  125. J. Seeliger, A. Werkmüller, and R. Winter, “Macromolecular crowding as a suppressor of human IAPP fibril formation and cytotoxicity,” PLoS ONE, vol. 8, no. 7, Article ID e69652, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. F. Meng, P. Marek, K. J. Potter, C. B. Verchere, and D. P. Raleigh, “Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of β-cell death,” Biochemistry, vol. 47, no. 22, pp. 6016–6024, 2008. View at Publisher · View at Google Scholar · View at Scopus